By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
There are a number of opportunities for foreign companies to invest in the Angolan pharmaceutical market. These opportunities include the development and production of pharmaceuticals, the distribution of pharmaceuticals, and the provision of healthcare services.
A large portion of Angola’s pharmaceuticals are imported, leading to increased costs and a reliance on foreign suppliers. Investing in the development and production of local pharmaceuticals would not only reduce costs but also enhance the country’s self-sufficiency in healthcare.
Geographical limitations and transportation challenges hinder access to healthcare in many parts of Angola. Telemedicine and remote healthcare services offer a promising solution to bridge this gap. Investing in telemedicine infrastructure aThe prevalence and increasing burden of disease, coupled with poor healthcare indicators, will contribute to long-term growth in the healthcare industry in Angola.
Training health workers has been part of a massive revitalisation of Angola’s health system. More than 200 students have been sent to Cuba, a long-time Angolan partner, to study medicine.
A key challenge to the healthcare industry is the limited access to healthcare services. Angola’s badly damaged infrastructure makes access to healthcare services and medicines very difficult for the population.
nd platforms could revolutionize healthcare delivery in Angola.
The growth of the market is being driven by increasing demand for pharmaceuticals, particularly for the treatment of chronic diseases such as malaria, HIV/AIDS, and tuberculosis.
The grim situation, the market consequently saw a dip in medicines sales which decreased by -21.3% in dollars and -23.9% in terms of units sold.
The Generic Medicines sales grew by both dollars and units, last year. This is indicative of the Angola being ready as a market to be invested in, especially with respect to generic medicines.
One of the most important factors to consider while investing in Angola, is the performance and workings of the distribution channels attributed to the medicine supply in the country.
In general health care provisions in Angola, are delivered mainly by the public sector. The emergence of private sector health care services has only recently begun, and will likely take more time, as their growth is mainly recorded in the urban cities, and more specifically, in the capital of Luanda.
Counterfeit drugs are a rising problem in Angola, and all over the African continent. Counterfeit pharmaceuticals are a concern in Angola, as are medicines sold under fake names.
The annual health budget in Angola steadily increased between 2016 and 2022 — showing a 299% growth, as it averaged 5.0% of the General State Budget.
The US Trade Representative Annual Foreign Trade Barriers Report (2015) pointed out the many roadblocks in the development of Angola’s foreign trade. This includes complicated and lengthy processes in customs, a high tariff rate, lack of industry and government transparency, shaky intellectual property rights, and sustain trade in the country.
Angola’s National Pharmacy Directorate and Ministry of Health oversee the country’s pharmaceutical industry.
To guarantee that pharmaceutical goods fulfill safety and efficacy criteria, these governmental entities regulate the registration of drugs, their importation, quality control, and distribution.
In order to make healthcare more inexpensive, generic medications are frequently used in Angola. Drugs sold under the generic name are often less expensive than those sold under brand names, which makes necessary treatments more accessible.
The provision of antiretroviral medications and malaria therapies to battle these diseases is crucially dependent on the pharmaceutical industry.
The healthcare overview of Angola highlights key statistics, developments, investments and other external variables that will assist healthcare companies, manufacturers and suppliers in either market entry and/or expansion.
The Angolan Government and foreign investors are channelling funds and resources into the rehabilitation and restructuring of the country’s infrastructure. By doing this Angola, has created opportunities in many industries including healthcare.
The Ministry of Health plans to revive its primary health care programme, concludes the analyst. This strategy represents the best way to deliver effective and comprehensive assistance to the population.
Total health expenditure in Angola is low overall, especially considering its growing population. It is heavily funded by Domestic Government Expenditure, but the largest source of financing is Domestic Private Expenditure, mostly Out-of-Pocket Expenses — which puts an enormous financial burden on households.
In terms of pharmacovigilance, ARMED improves ability to prevent medications from losing their therapeutic characteristics and from inducing adverse responses in patients.It also tracks medical items along the whole supply chain of the cold storage system.
Angola has a long way to go to achieve universal health coverage and for that it requires a greater financial commitment on behalf of its Government.
The Angola pharmaceutical market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
